Nabriva Therapeutics plc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenues
Product revenue, net
Collaboration revenue
Research premium and grant revenue
Total revenues
Operating expenses:
Cost of revenues
Loss on inventory commitments
Research and development expenses
General and administrative
Selling, general and administrative expenses
Total operating expenses

Loss from operations
Other income (expense):
Other income, net
Interest income
Interest expense, net
Loss on extinguishment of debt
Loss before income taxes
Income tax expense
Net loss
Loss per share
Basic and Diluted ($ per share)
Basic and Diluted
Basic loss ($ per share)
Diluted loss ($ per share)
Weighted average number of shares:
Basic (in shares)
Diluted (in shares)

Comments